Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Clin Immunol. 2015 Apr 11;158(2):183–192. doi: 10.1016/j.clim.2015.04.001

Figure 4. Trpv2 agonists significantly reduced clinical arthritis inflammation and severity in vivo.

Figure 4

(A) C57BL/6 mice were injected with KRN arthritogenic serum. O1821 (10mg/Kg BID IP) was started after the onset of arthritis (day 3; D3, black arrow) and continued through day nine (D9). O1821-treated mice had reductions in arthritis severity scores that were evident as early as day five (D5) and reached statistical significance on days seven and eight (* D6: P=0.091; # D7: P=0.002; ¶ D8: P=0.045; mean±SEM ; t-test). (B) DBA1/J mice with collagen-induced arthritis (CIA) treated with LER13 (n=8 per treatment group) (treatment started on D10 following the first immunization, black arrow) had a significant reduction in arthritis severity and clinical signs of inflammation compared with the vehicle group (figure 6B). CIA onset is typically around D21 following immunization, and the disease-protecting effect was detected by day 31 (D31) and persisted through the end of the arthritis scoring period at day 76 (D76), with a reduction of 50% in mean cumulative arthritis scores (arthritis severity index, ASI; mean±S.D.: control=80±21.8 and LER18 40.7±36.8; p=0.023, t-test), compared with control vehicle.